INDIANAPOLIS (dpa-AFX) - Drug maker Eli Lilly and Co. (LLY) and biopharmaceutical company Incyte Corporation (INCY) Thursday announced 52-week efficacy and safety data from the open-label, long-term extension of the Phase 2b JADA study of baricitinib in patients with active rheumatoid arthritis. The results were presented at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology.
Baricitinib, formerly LY3009104 (INCB28050), is an orally available Janus kinase or JAK inhibitor being studied for use in the treatment of certain autoimmune conditions, including rheumatoid arthritis.
In the initial 12-week portion of this study, baricitinib was associated with statistically significant improvements in the signs and symptoms of rheumatoid arthritis disease versus placebo and these responses were maintained or improved during an additional 12 weeks of blinded treatment.
Copyright RTT News/dpa-AFX
Kostenloser Wertpapierhandel auf Smartbroker.de